hotspot -WSS

hotspot

author：leisure time 2025-10-03 00:38:27 - browse：3

A pile of Zynex Medical batteries and electrode pads are seen at Michelle Bean's home — A pile of Zynex Medical batteries and electrode pads Kayana Szymczak for STAT

Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need.

STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees. Here are five takeaways.

The ‘razor blade’ business model

Zynex sells nerve and muscle stimulation machines, known as TENS and EMS units, to treat pain and soothe muscles. But the company makes most of its money from monthly shipments of batteries and electrodes — almost 70% of its $184 million revenue in 2023 came from these supplies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Van's Gluten Free Original Waffles recalled for possible wheat allergen

WSS

Senate panel to vote on hospitals, PBMs, prisoner care

New case study details death in closely watched Alzhiemer's trial

Listen: Biogen's messy board & Laronde's data problem

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Biden's order seeks to regulate AI risk without stifling innovation

Inside the fall of star MIT scientist David Sabatini

explore

hotspot

The ‘razor blade’ business model

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

The high cost of giving birth even with insurance

New case study details death in closely watched Alzhiemer's trial

Walensky prepares to leave CDC — and Congress — behind

7 people shot in DC, police say

Medical leaders decry Supreme Court decision on affirmative action

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Malaria cases in Florida and Texas: Here’s what you need to know

Eli Lilly to pay $200M for Beam’s stake in gene

Medical leaders decry Supreme Court decision on affirmative action

PhRMA sues HHS over Medicare drug price negotiation

entertainment

A new study asks: Are we harming blood donors by taking blood?

Listen: PBM conflicts, RSV vaccines, & the future of flu season

The pink breast cancer awareness ribbon needs a redesign

Readout Newsletter: What happened with Sarepta's Duchenne data

A new study asks: Are we harming blood donors by taking blood?

Grail is spending more than ever lobbying Congress

knowledge

knowledge

Wikipedia

hotspot